NCT02430363 - Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

June 30, 2018

Conditions

Glioblastoma

Interventions

DRUG

MK - 3475

Administered Intravenously

BIOLOGICAL

Suppressor of the PI3K/Akt pathways

Capsules orally with food

Trial Locations (13)

St Johannes Hospital, Duisburg

Regional Cancer Center, Dnipro

Lower-Silesian Oncology Centre, Wroclaw

M D Anderson Cancer Center, Houston

Pavlov State Medical University, Saint Petersburg

Dana-Farber Cancer Institute, Boston

UCL- Cliniques Universitaires Saint Luc, Brussels

Spedali Civili di Brescia, Brescia

IRCCS San Raffaele, Milan

Hospital Universitario Germans Trias I Pujol, Barcelona

Universitätsklinik für Frauenheilkunde, Bern

National Institute of Cancer, Kiev

Royal Victoria Hospital, Belfast